Development of a novel β-secretase binding assay using the AlphaScreen platform.

@article{Ren2013DevelopmentOA,
  title={Development of a novel β-secretase binding assay using the AlphaScreen platform.},
  author={Zhao Hua Ren and Danny W H Tam and Ying-zi Xu and David W. G. Wone and Shendong Yuan and Hing Leung Sham and Harry Cheung and Karin Regnstrom and Xiaohua Chen and Donald Rudolph and Michael F. Jobling and Dean R. Artis and Michael P. Bova},
  journal={Journal of biomolecular screening},
  year={2013},
  volume={18 6},
  pages={
          695-704
        }
}
Alzheimer's disease (AD) is a devastating neurodegenerative disease affecting millions of people. β-secretase-1 (BACE1), an enzyme involved in the processing of the amyloid precursor protein (APP) to form Aβ is a validated target for AD. Herein, the authors develop and validate a novel binding assay for BACE1 using the AlphaScreen platform that is amenable for high-throughput screening (HTS). Small-molecule BACE1 inhibitors of the hydroxyethylamine, hydantoin, and sulfamide classes were… CONTINUE READING
BETA

References

Publications referenced by this paper.
SHOWING 1-10 OF 32 REFERENCES

The β-secretase, BACE

  • Journal of Molecular Neuroscience
  • 2001
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

β-Secretases, Alzheimer's Disease, and Down Syndrome

  • Current gerontology and geriatrics research
  • 2012
VIEW 1 EXCERPT

Alzheimer ’ s disease facts and figures

R. Terry, L. Hansen, E. Masliah
  • Alzheimers Dement
  • 2012

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.

  • The Journal of neuroscience : the official journal of the Society for Neuroscience
  • 2011

Similar Papers

Loading similar papers…